Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2001

01-08-2001

N-Methylformamide in Advanced Squamous Cancer of the Uterine Cervix: An Eastern Cooperative Oncology Group Phase II Trial

Authors: Lakshmi Rajdev, Zi-Fan Yu, Scott Wadler, Edie Weller, S. Benham Kahn, Douglass Tormey, Roland Skeel, Peter H. Wiernik

Published in: Investigational New Drugs | Issue 3/2001

Login to get access
Metadata
Title
N-Methylformamide in Advanced Squamous Cancer of the Uterine Cervix: An Eastern Cooperative Oncology Group Phase II Trial
Authors
Lakshmi Rajdev
Zi-Fan Yu
Scott Wadler
Edie Weller
S. Benham Kahn
Douglass Tormey
Roland Skeel
Peter H. Wiernik
Publication date
01-08-2001
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2001
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1010672618269

Other articles of this Issue 3/2001

Investigational New Drugs 3/2001 Go to the issue

OriginalPaper

A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

OriginalPaper

Tetramethylpiperidine-Substituted Phenazines Inhibit the Proliferation of Intrinsically Multidrug Resistant Carcinoma Cell Lines

OriginalPaper

Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells

Instructions for Authors

Instructions for Authors

OriginalPaper

Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study

OriginalPaper

Phase II Trial of GM-CSF in Advanced Prostate Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits